Alimentary Pharmacology Therapeutics:经腹电刺激可以改善功能性便秘妇女的症状

2020-04-06 MedSci原创 MedSci原创

功能性便秘妇女通常对泻药治疗很排斥,因此治疗慢性便秘具有挑战性。目前儿童中使用经腹电干扰疗法显示出了巨大益处,但成人研究不足。因此,本项研究旨在评估经腹干扰对难治性便秘妇女肠道症状和生活质量。

背景:功能性便秘妇女通常对泻药治疗很排斥,因此治疗慢性便秘具有挑战性。目前儿童中使用经腹电干扰疗法显示出了巨大益处,但成人研究不足。因此,本项研究旨在评估经腹干扰对难治性便秘妇女肠道症状和生活质量的影响。

方法:研究人员在单盲,随机对照试验中,对≥18岁顽固性便秘的妇女随机接受干扰刺激(电流交叉)或新型假刺激(电流不交叉)1小时。持续6周。主要观察结局是每周自发排便次数≥3的患者人数。次要终点包括PAC-SYM(便秘患者的症状评估),PAC-QOL(便秘患者的生活质量评估)和总体症状严重程度评分(在基线,刺激中点,治疗结束时测量)的变化。

结果:干预疗法(n = 17)达到主要结果的比例为53%,而假手术(n = 16)的比例为12%(P= 0.02)。干扰疗法可降低PAC-SYM(P= 0.03)和总体症状评分(P= 0.05)。干扰疗法的轻泻剂使用率为66%,而假疗法为14%(P= 0.01)。症状结局显着改善维持3个月。

结论:经腹干扰性电刺激可有效减少成年女性的便秘。治疗后三个月,反应得以维持,生活质量得到改善。

原始出处:

Judith S. Moore. Et al. Randomised clinical trial: transabdominal interferential electrical stimulation vs sham stimulation in women with functional constipation. Alimentary Pharmacology Therapeutics.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-06-13 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-06-09 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1728391, encodeId=53fe1e2839106, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 13 12:43:07 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908581, encodeId=ceee19085817d, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 03 05:43:07 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787658, encodeId=04e11e8765819, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 11 07:43:07 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739010, encodeId=8c311e3901055, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 02 08:43:07 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996345, encodeId=62f91996345f9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jun 09 17:43:07 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915527, encodeId=5edc191552ef5, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Apr 17 08:43:07 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788668, encodeId=fdf61e8866896, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Mon Jun 08 20:43:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788386, encodeId=230b1e8838638, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 21 02:43:07 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971128, encodeId=68be19e112855, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Dec 31 10:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974393, encodeId=605f19e4393e4, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Dec 31 02:43:07 CST 2020, time=2020-12-31, status=1, ipAttribution=)]

相关资讯

中国老年人便秘评估技术应用共识(草案)

慢性便秘严重影响老年人生活,需反复就医消耗大量费用,而更多的老年人自行滥用各种泻药,导致依赖药物,甚至发生结肠黑变病,可能诱发或加重肛裂、痔疮、反复发生不全肠梗阻、肠穿孔、疝气、结肠癌、阿尔茨海默病、心脑血管疾病,从而造成更加严重后果。 目前老年人慢性便秘已成为一个各国面临的老龄化社会问题,因此建立一个科学、全面、有效的评估体系,就成为我们刻不容缓的亟待解决的临床问题。

2019 MASCC建议:晚期癌症患者便秘的管理

2019年8月,癌症支持疗法多国学会(MASCC)发布了晚期癌症患者便秘的管理建议,专家组共提出15条推荐,内容涉及便秘的评估,治疗和再评估。为晚期癌症便秘的治疗提供指导。

病例:反复腹泻多年,近几月便秘

患者男性,33岁,腹泻多年,每天排便3~5次,溏薄,有少量黏冻,无血,进食生冷食物后更容易腹泻,有时左下腹疼痛,解大便后能缓解。近3月大便不畅,费力难解,3~4天一次,无便血。

证据:住院患者如何预防便秘?便秘患者如何合理饮食?

临床问题住院患者如何预防便秘?便秘患者如何合理饮食?相关背景便秘是指排便次数减少(每周少于3次)、粪便量减少、粪便干结、排便费力,便秘患者常常用泻药甚至采用灌肠治疗1,2。便秘是住院患者最常见的不适症状之一。便秘是可以预防的。那么,住院患者如何预防便秘?便秘患者如何合理饮食以改善排便困难的现象?对该领域的证据进行总结如下:证据描述导致人们产生排便冲动的排便反射往往持续数分钟后即消失,而且可能数小时

六年“绿丝带行动” :“肠”久关爱,跑赢便秘马拉松

国产阿卡波糖片花费的3285元会相对节省一些,但老张还是选择了进口药。拥有城乡居民医保的老张在家门口的一级医院门诊就诊,使用进口拜唐苹需要自付2223元。

便秘+拉肚子,反反复复,最后竟被诊断为这个病?!

肠易激综合征(irritable bowel syndrome,IBS)是一种常见的慢性功能性的胃肠疾病,临床分别表现为腹泻、便秘及交替性的腹泻和便秘,每一种类型还可能伴随腹痛、腹胀等症状。基于目前较为公认的罗马 III 诊断标准,IBS 可进一步分为腹泻型(IBS-D)、便秘型(IBS-C)、混合型(IBS-M)和不定型(IBS-U)4 个亚型。IBS发病机制尚不完全清楚,目前尚缺乏根治性方法。